Anton Lindqvist

Company: Diamyd

Job title: Chief Scientific Officer

Seminars:

Updates on the Phase 3 Trial for an Antigen Specific Immune Tolerance Therapy for Type 1 Diabetes 8:30 am

• Discussing considerations for late-stage clinical trials for antigen-specific approached to treating TD1 • Acknowledging regulatory requirements for precision medicine approaches for autoimmune diseases • Navigating the use of a surrogate endpoint for BLA submission of precision medicine approachesRead more

day: Conference Day One